Cambridge, United States
Prime Medicine, Inc., founded in 2019 and based in the United States, is pioneering the field of Biotechnology and Life Sciences with its innovative Prime Editing technology. With their slogan, "Delivering on the promise of Prime Editing," the company aims to revolutionize gene therapy by offering a tool that can effectively ‘search and replace’ faulty DNA to restore normal function. This advanced technology holds the potential to address over 90% of known disease-causing genetic mutations.
Prime Medicine envisions a future where genetic diseases are not only treated but also prevented, thus significantly improving patient outcomes. The company is actively building a diverse and passionate team to fuel this transformative journey.
The most recent funding for Prime Medicine, Inc. was a substantial $144.20M grant investment received on 01 August 2025. Although the investors remain undisclosed, this investment underscores significant trust and interest in the potential impact of Prime Editing on healthcare.
